Advertisement

Topics

Sankyo Co., Ltd. Company Profile

15:30 EDT 18th September 2018 | BioPortfolio

Since Sankyo's founding, the Company has been continuously motivated by an unstinting drive to bring new pharmaceuticals to market. This introduction to Sankyo's progress to date will reveal the eagerness to confront new challenges that animates our operations, and the global stance to which this has led us.

Location

5-1, Nihonbashi Honcho 3-chome
Chuo-ku
Chuo-ku
103-8426
Japan

Contact

Phone: 03-5255-7111


News Articles [81 Associated News Articles listed on BioPortfolio]

Daiichi Sankyo to restructure vaccines subsidiary

Daiichi Sankyo is set to restructure its wholly-owned Kitasato Daiichi Sankyo Vaccine subsidiary into a specialised manufacturing division to enhance...Read More... The post Daiichi Sankyo to restruct...

Glycotope GmbH: Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate

TOKYO, BERLIN, BASKING RIDGE, NJ / ACCESSWIRE / July 30, 2018 / Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Glycotope GmbH (hereafter, Glycotope) have entered into an exclusive ...

Daiichi Sankyo to develop new inflammatory disease drugs

Daiichi Sankyo has formed a new consortium focused on research and discovery of medicines over a period of five years...Read More... The post Daiichi Sankyo to develop new inflammatory disease drugs a...

BRIEF—Daiichi Sankyo US reorganization means 280 job cuts

Japanese pharma major Daiichi Sankyo says it will reorganize its US commercial organization as it continues…

FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo’s FLT3 Inhibitor Quizartinib for Relapsed/Refractory FLT3-ITD AML

Tokyo, Munich and Basking Ridge, NJ – (August 1, 2018) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthr...

Daiichi Sankyo reports on results for leukemia candidate

Daiichi Sankyo's quizartinib, a drug being tested in a Phase III trial as a treatment for patients with relapsed or refractor -More- 

Daiichi Sankyo transfers 41 products to Alfresa Pharma

Daiichi Sankyo has announced plans to split and transfer its inventories to Alfresa Pharma, along with Japanese manufacturing and sales...Read More... The post Daiichi Sankyo transfers 41 products to ...

Daiichi Sankyo Presents Phase 3 ENLIVEN Study of Pexidartinib, Demonstrating Statistically Significant Clinical Improvement Across Multiple Endpoints in Patients with Tenosynovial Giant Cell Tumor

Tokyo, Basking Ridge, NJ, and Munich – (June 4, 2018) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the phase 3 ENLIVEN study showed a statistically significan...

Drugs and Medications [7 Associated Drugs and Medications listed on BioPortfolio]

Benicar [Daiichi Sankyo, Inc]

These highlights do not include all the information needed to use Benicar safely and effectively. See full prescribing information for Benicar. Benicar (olmesartan medoxomil) tablets Initial U.S. Appr...

Evoxac capsules(cevimeline hydrochloride) [Daiichi Sankyo Pharma Development]

EVOXAC Capsules(cevimeline hydrochloride)

Azor [Daiichi Sankyo, Inc.]

These highlights do not include all the information needed to use AZOR safely and effectively. See full prescribing information for AZOR. AZOR (amlodipine and olmesartan medoxomil) tablets, for oral u...

Benicar hct [Cardinal Health]

Benicar HCT® Tablets(Olmesartan Medoxomil-Hydrochlorothiazide)

Benicar hct [Physicians Total Care, Inc.]

PubMed Articles [0 Results]

None

Clinical Trials [12 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Olmesartan Medoxomil Tablet Under Fasting Conditions

Subjects to compare the single dose bioavailability of Torrent's Olmesartan Medoxomil Tablets 40 mg and Benicar 40 mg Tablets of Daichi Sankyo Inc. USA. Dosing periods of studies were sepa...

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Olmesartan Medoxomil Tablets Under Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Olmesartan Medoxomil Tablets 40 mg and Benicar® 40 mg Tablets of Daiichi Sankyo Inc., USA. Dosing periods of studies were ...

BE Study of Torrent's Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Tab - Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide Tablets 40+10+25 mg and Tribenzor® 40+10+25 mg Tablets of Daichi ...

Bioequivalence Study of Torrent's Olmesartan Medoxomil, Amlodipine and Hydrochloride Tablets Under Fasting Conditions.

Subjects to compare the single dose bioavailability of Torrent's Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide Tablets 40+10+25 mg and Tribenzor® 40+10+25 mg Tablets of Daichi ...

Comparative Study of Loxoprofen Sodium Transdermal Patch and Loxonin® Tablets for the Treatment of Acute Trauma

This study evaluates the non-inferiority of the new transdermal patch dosage form containing loxoprofen sodium (100 mg - Daiichi-Sankyo) in comparison with oral Loxonin® (60 mg tablet - D...

Companies [23 Associated Companies listed on BioPortfolio]

Sankyo Co., Ltd.

Since Sankyo's founding, the Company has been continuously motivated by an unstinting drive to bring new pharmaceuticals to market. This introduction to Sankyo's progress to date will reveal the eager...

DAIICHI SANKYO EUROPE GmbH and SHARE

DAIICHI SANKYO is a global pharmaceutical company that focuses on researching and marketing innovative medications. The company was created in 2005 through the merger of two traditional Japanese e...

Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. ...

Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited, established in 2005 after the joint share transfer of two leading century-old Japanese pharmaceutical companies, is continuously generating innovative drugs that e...

ArQule, Inc. and Daiichi Sankyo Company, Limited

On December 19, 2008, ArQule and Daiichi Sankyo, Co., Ltd. signed a license, co-development and co-commercialization agreement to co-develop tivantinib in the U.S., Europe, South ...

More Information about "Sankyo Co., Ltd." on BioPortfolio

We have published hundreds of Sankyo Co., Ltd. news stories on BioPortfolio along with dozens of Sankyo Co., Ltd. Clinical Trials and PubMed Articles about Sankyo Co., Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Sankyo Co., Ltd. Companies in our database. You can also find out about relevant Sankyo Co., Ltd. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record